1045 related articles for article (PubMed ID: 20132216)
1. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
[TBL] [Abstract][Full Text] [Related]
2. Proteomics and Transcriptomics of BJAB Cells Expressing the Epstein-Barr Virus Noncoding RNAs EBER1 and EBER2.
Pimienta G; Fok V; Haslip M; Nagy M; Takyar S; Steitz JA
PLoS One; 2015; 10(6):e0124638. PubMed ID: 26121143
[TBL] [Abstract][Full Text] [Related]
3. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
4. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription.
Liu CD; Lee HL; Peng CW
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781
[TBL] [Abstract][Full Text] [Related]
5. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1.
Watanabe A; Maruo S; Ito T; Ito M; Katsumura KR; Takada K
J Virol; 2010 Mar; 84(6):2893-901. PubMed ID: 20042495
[TBL] [Abstract][Full Text] [Related]
7. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
[TBL] [Abstract][Full Text] [Related]
8. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
[TBL] [Abstract][Full Text] [Related]
9. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
10. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
11. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
Schlager S; Speck SH; Woisetschläger M
J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
[TBL] [Abstract][Full Text] [Related]
12. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
[TBL] [Abstract][Full Text] [Related]
14. Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.
Murray RJ; Young LS; Calender A; Gregory CD; Rowe M; Lenoir GM; Rickinson AB
J Virol; 1988 Mar; 62(3):894-901. PubMed ID: 2828684
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.
Kelly GL; Milner AE; Tierney RJ; Croom-Carter DS; Altmann M; Hammerschmidt W; Bell AI; Rickinson AB
J Virol; 2005 Aug; 79(16):10709-17. PubMed ID: 16051863
[TBL] [Abstract][Full Text] [Related]
16. Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature.
Kelly GL; Stylianou J; Rasaiyaah J; Wei W; Thomas W; Croom-Carter D; Kohler C; Spang R; Woodman C; Kellam P; Rickinson AB; Bell AI
J Virol; 2013 Mar; 87(5):2882-94. PubMed ID: 23269792
[TBL] [Abstract][Full Text] [Related]
17. Analysis of viral gene expression and genome persistence in CD23-positive and -negative subpopulations of Epstein-Barr-virus-infected BL2 cells.
Doyle MG; Crawford DH
Intervirology; 1994; 37(5):236-44. PubMed ID: 7698878
[TBL] [Abstract][Full Text] [Related]
18. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
19. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
[TBL] [Abstract][Full Text] [Related]
20. Dual EBNA1 promoter usage by Epstein-Barr virus in human B-cell lines expressing unique intermediate cellular phenotypes.
Taylor KA; Wetzel S; Lyles DS; Pollok BA
J Virol; 1994 Oct; 68(10):6421-31. PubMed ID: 8083980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]